Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Nkarta Inc
NKTXCurrent price
1.66 USD
-0.08 USD (-4.60%)
Last closed
1.72 USD
Company
www.nkartatx.com
ISIN
US65487U1088
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
163 013 920 USD
Yield for 12 month
-86.35 %
1Y
3Y
5Y
10Y
15Y
NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. Address: 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
15.83 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-5 869 000 USD
Last Year
-6 572 000 USD
Current Quarter
–
Last Quarter
-2 262 000 USD
Key Figures NKTX
1 year
3 years
5 years
10 years
EBITDA
-118 141 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-16.96 %
PEG Ratio
–
Return On Equity TTM
-30.40 %
Wall Street Target Price
15.83 USD
Revenue TTM
385 USD
Book Value
6.11 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
-36 220 000 USD
Earnings per share
-1.81 USD
Diluted Eps TTM
-1.81 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics NKTX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History NKTX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation NKTX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
1 000 000.00
Price Sales TTM
1 000 000.00
Enterprise Value EBITDA
0.95
Price Book MRQ
0.38
Financials NKTX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators NKTX
For 52 weeks
2.22 USD
16.24 USD
50 Day MA
3.19 USD
Shares Short Prior Month
6 771 959
200 Day MA
6.15 USD
Short Ratio
5.44
Shares Short
6 646 819
Short Percent
12.49 %
BeatStart